Abstracts tagged "osteoporosis"

Abstract Number: 1029 • ACR Convergence 2024
An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network
Benjamin Wolff¹, Ryan Bigelsen², Kathryn Zaffiri², Susan Kim³ and Philip Dunn⁴, ¹Lehigh Valley Health Network, Macungie, PA, ²Lehigh Valley Health Network, Allentown, PA, ³Lehigh Valley Hospital Network, Allentown, PA, ⁴Lehigh Valley Health Network, Emmaus, PA
Background/Purpose: Osteoporosis is a widely recognized disease of the bone where bone mineral density is decreased leading to increased risk for fracture. Bone mineral density…
Abstract Number: 2118 • ACR Convergence 2024
Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis
Yen-An Chang¹ and Ming‑Han Chen², ¹Division of Allergy, Immunology, Rheumatology/Department of Medicint/Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…
Abstract Number: 2140 • ACR Convergence 2024
Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis
Katherine Wysham¹, Hannah Brubeck², Kylie Riggles³, Riley Bass⁴, Elizabeth Wahl², Radhika Narla⁵, Namrata Singh⁶, ariela orkaby⁷, Joshua Baker⁸, Patricia Katz⁹, Dolores Shoback¹⁰ and Jose Garcia¹¹, ¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA Puget Sound Health Care System, Bellevue, WA, ⁴VA Puget Sound Health Care System, Seattle, ⁵VA Puget Sound Healthcare System, Seattle, WA, Seattle, WA, ⁶University of Washington, Bellevue, WA, ⁷New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰San Francisco VA/University of California, San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System/University of Washington, Seattle, WA
Background/Purpose: Frailty represents a state of increased vulnerability to poor outcomes after physiologic stressors, and occurs at higher rates and younger ages in RA. Frailty…
Abstract Number: 1033 • ACR Convergence 2024
Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020
Muhammad Naveed¹, Farman Ali², Ahila Ali¹, Bazil Azeem³, Faizan Ahmed⁴, Rabia Iqbal¹, Muhammad Omer Rehan¹, Nouman Shafique⁵, Syed Ishaq⁶, Aman Ullah⁷ and Sherif Eltawansy⁸, ¹Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, ²Corewell Health, Dearborn Hospital, Dearborn, MI, Dearborn, MI, ³Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, ⁴Ameer-ud-Din Medical College, Lahore, Pakistan, ⁵AdventHealth Orlando, Orlando, FL, ⁶Sinai Hospital of Baltimore, Baltimore, MD, ⁷SSM Health St Louis University Hospital, St. Louis, MO, ⁸Jersey Shore University Medical Centre, Neptune, NJ
Background/Purpose: Osteoporosis and cardiovascular disease (CVD) represent significant public health concerns. This study investigates the trends and demographic disparities in mortality due to osteoporosis and…
Abstract Number: 2120 • ACR Convergence 2024
EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry
BEATRIZ ROSA¹, Melissa Fraga¹, Erica Barbosa¹, Jade Dib Fernandez², Marcelo Pinheiro³ and Maria Teresa Terreri⁴, ¹Universidade Federal de São Paulo, São Paulo, SP, Brazil, ²UNIFESP-EPM, São Paulo, SP, Brazil, ³UNIFESP/ EPM, São Paulo, SP, Brazil, ⁴UNIFESP, São Paulo, SP, Brazil
Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease associated with bone mass loss. This loss can be evaluated by using the bone…
Abstract Number: 2141 • ACR Convergence 2024
Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Marlene Marte Furment¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: The majority of bone loss happens within 6 months of glucocorticoid treatment. Per the 2022 American College of Rheumatology (ACR) Glucocorticoid-Induced Osteoporosis Guidelines it…
Abstract Number: 1055 • ACR Convergence 2024
Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis
Ye Liu¹, Jingyi Zhang¹, Tarun Arora², Bisakha Sen¹, Kenneth Saag³ and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medicare Part B drug expenditures have increased due to the rising use of expensive specialty drugs like provider-administered biologics. These medications can also be…
Abstract Number: 2122 • ACR Convergence 2024
Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis
Jaspreet Bahia¹, Christian Steppe², Hannah Brubeck³, Radhika Narla², George Mount⁴, Elizabeth Wahl⁵ and Katherine Wysham⁶, ¹University of Washington, SEATTLE, WA, ²VA Puget Sound Healthcare System, Seattle, WA, Seattle, WA, ³VA Puget Sound Health Care System, Seattle, WA, ⁴Madigan Army Medical Center, Lakewood, WA, ⁵VA Puget Sound Healthcare System, Seattle, WA, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) accelerates bone loss and increases fracture risk. We evaluated GIOP screening and prescribing patterns in our Veterans Affairs (VA)-based academic…
Abstract Number: 2142 • ACR Convergence 2024
Comparison of Bone Mineral Density at the Distal Radius, Hip, and Lumbar Spine in Female Patients Undergoing Surgery for Proximal Femur or Distal Radius Fractures: Implications for Osteoporosis Diagnosis
KEN NAKASEKO, Department of Orthopaedic Surgery and Rheumatology, Kuwana City Medical Center, Kuwana Mie, Japan
Background/Purpose: Osteoporosis is often diagnosed based on bone mineral density (BMD) measurements at the hip or lumbar spine. However, our previous study reported that 38%…
Abstract Number: 1061 • ACR Convergence 2024
Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment
Anupama Shahane¹, Marissa Blum², Andrew Kanoff³, Kristel Frey⁴, Sean Looby⁵ and Nora Sandorfi¹, ¹University of Pennsylvania, Philadelphia, PA, ²Temple University Health System, Philadelphia PA, Philadelphia, ³University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia PA, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia PA, Philadelphia
Background/Purpose: Osteoporosis is the most common bone disease leading to fragility fractures associated with significant morbidity and increased mortality (1). Glucocorticoids (GC) are widely used…
Abstract Number: 2123 • ACR Convergence 2024
Epidemiology of Bone Health and Fracture in Gout Patients
Emily Holladay¹, Alexis Woods², Lissa Padnick-Silver³, Fenglong xie⁴, Jingyi Zhang⁵, Angelo Gaffo⁵, Jeffrey Curtis⁶ and Brian LaMoreaux², ¹University of Alabama at Birmingham, Edmond, OK, ²Amgen, Thousand Oaks, CA, ³Amgen, Thousand Oaks, ⁴University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶FASTER Medicine, Hoover, AL
Background/Purpose: Gout is an erosive arthropathy, and gout patients have been shown to have a higher occurrence of osteoporosis and fracture. This study evaluated bone…
Abstract Number: 2143 • ACR Convergence 2024
Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population
Marina soledad Moreno Garcia¹, Roxana González Mazario², yedra uson Rodriguez³, Erardo meriño Ibarra⁴, Emilio Giner⁵, Juan Carlos Cobeta García⁶, Marilia Arce Benavente⁷, maria Dolores Fábregas canales⁸, Julia Ullier Bellmunt³, Giuliano Boselli³, pilar martinez Valles⁷, Jorge Juan Fragío Gil⁹, carlos Vazquez Galeano⁷ and Ana Turrion Nieves¹⁰, ¹hospital Miguel Servet . Zaragoza, Zaragoza, Aragon, Spain, ²Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ³hospital miguel servet, zaragoza, Aragon, Spain, ⁴Hospital San Jorge Huesca, zaragoza, ⁵Hospital Royo Villanova, Teruel, Spain, ⁶Hospital Ernest Lluch, zaragoza, ⁷hospital miguel servet, Zaragoza, ⁸Hospital de Barbastro, Huesca, Spain, ⁹Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ¹⁰Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain
Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…
Abstract Number: 1066 • ACR Convergence 2024
Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics
Krista Topalsky¹, Lee Arphai², Mary Ellen Amos², Amanda Mertz², Christopher Blum³, Timothy Godbey², Lori Leonard², Maya Mattar⁴, Elizabeth Cable² and Robert Wenzell², ¹University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ²Cleveland VA Medical Center, Cleveland, OH, ³Cleveland VA Medical Center, Cleveland, ⁴Louis Stokes VA medical Center, Mayfield Heights, OH
Background/Purpose: Osteoporosis is a major public health concern in the United States, leading to significant morbidity, mortality, and increased economic burden. Fractures are projected to…
Abstract Number: 2126 • ACR Convergence 2024
Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study
Carmen Gomez Vaquero¹, Marta Domínguez-Álvaro², Daniel Seoane-Mato³, Pilar Peris⁴, Santos Castañeda⁵, Eduardo Kanterewicz Binstock⁶, Ramon Mazzucchelli⁷, Luis Arboleya⁸, Miguel Bernad⁹, Antonio Alvarez-Cienfuegos¹⁰, Blanca Correa¹¹, Luis-Maria Jimenez-Liñan¹², Carmen Mateo-Pascual¹³, Mª Mercedes Molina del Rio¹⁴, Mercedes Retamal-Ortiz¹⁵, Aida Fatima Lopez-Laguna¹⁶, Ruth Molera-Valero¹⁷, Sara Alvar-Pariente¹⁸, Antonio Pascual¹⁹, Adolfo Arias-Senso²⁰, Nuria Perez-Gutierrez²¹, Soledad Garcia-Frias²², David Bouza-Alvarez²³, Susana Sostres²⁴, Daniel Suarez-Hernandez²⁵, Ana Zamora-Casal²⁶, Cristina Garcia-Ramirez²⁷ and Enrique González-Dávila²⁸, and OsteoSER Project Collaborative Group, ¹Hospital Universitari de Bellvitge, 08907 L'Hospitalet, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Madrid, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital Universitari de Vic (Consorci Hospitalari de Vic), Barcelona, Spain, ⁷Hospital Universitario Fundacion Alcorcon, Madrid, Spain, ⁸Hospital Universitario Central de Asturias, Oviedo, Spain, ⁹Hospital Universitario La Paz, Madrid, Spain, ¹⁰Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain, ¹¹Clínica Sanz y Correa, A Coruña, Spain, ¹²Hospital Don Benito-Villanueva, Don Benito, Spain, ¹³Centro de Salud Fuencarral, distrito Fuencarral-El Pardo, Madrid, Spain, ¹⁴Centro de Atención Primaria Viladecans Montbaig, Sant Climent de Llobregat, Spain, ¹⁵Centro de Salud Don Benito Oeste, Don Benito, Spain, ¹⁶Centro de Salud El Molar, El Molar, Spain, ¹⁷Centro de Salud Orihuela 1-El Rabaloche, Orihuela, Spain, ¹⁸Centro de Salud Malpica, Malpica, Spain, ¹⁹Centro de salud Ronda-Norte y Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁰Centro de Salud de Santa Amalia, Santa Amalia, Spain, ²¹Centro de Atención Primaria Ramona Via i Pros, El Prat de Llobregat, Spain, ²²Centro de Salud de Cortes de la Frontera, Cortes de la Frontera, Spain, ²³Centro de Salud Elviña Mesoiro, A Coruña, Spain, ²⁴Centro de Atención Primaria Cap 17 de setembre, El Prat de Llobregat, Spain, ²⁵Centro de Salud de Benejuzar, Benezujar, Spain, ²⁶Centro de Salud Os Mallos, A Coruña, Spain, ²⁷Centro de Salud Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁸Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain
Background/Purpose: The bone mineral density (BMD) reference data for the Spanish population comes from the study Multicentre Research Project on Osteoporosis (MPRO), concluded in 1989.Our…
Abstract Number: 2145 • ACR Convergence 2024
Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta.
Daniel Ramos Castro¹, SAMUEL LEAL², Elena Grau García³, JOSE ELOY OLLER RODRIGUEZ⁴, José Ivorra-Cortés⁵, Carmen Riesco Barcena⁶, Anderson Huaylla Quispe⁷, Pablo Muñoz Martínez⁸, Laura Mas Sánchez⁹, Alba Torrat noves¹⁰, Belén Villanueva Mañés¹¹, Iago Alcántara Álvarez¹², Andrés Pérez Hurtado¹, Miguel Simeo Vinaixa¹¹ and Jose A Román-Ivorra¹³, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Hospital La Fe, Valencia, Spain, ³HUP La Fe, Valencia, Spain, ⁴HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁵Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁶Hospital Universitario i Politecnic La Fe (Valencia-Spain), Valéncia, Spain, ⁷Medicina, Valéncia, Spain, ⁸Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁹Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ¹¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valéncia, Comunidad Valenciana, Spain, ¹³Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder (90% autosomal dominant) characterized by a disruption in type 1 collagen or proteins associated with…

1
2
3
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].